EUR 1.97
(0.71%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | -3.62 Million EUR | 0.0% |
2022 | - EUR | -100.0% |
2021 | 10.76 Million EUR | 0.0% |
2020 | - EUR | 0.0% |
2019 | - EUR | 0.0% |
2018 | - EUR | 0.0% |
2017 | - EUR | 0.0% |
2016 | - EUR | 0.0% |
2015 | - EUR | 0.0% |
2014 | - EUR | 0.0% |
2013 | - EUR | -100.0% |
2012 | 6000.00 EUR | -71.43% |
2011 | 21 Thousand EUR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q2 | - EUR | 0.0% |
2023 FY | -3.62 Million EUR | 0.0% |
2023 Q2 | - EUR | 0.0% |
2023 Q4 | -3.62 Million EUR | 0.0% |
2022 Q4 | - EUR | 0.0% |
2022 FY | - EUR | -100.0% |
2022 Q2 | - EUR | 0.0% |
2021 Q4 | 10.76 Million EUR | 0.0% |
2021 Q2 | - EUR | 0.0% |
2021 FY | 10.76 Million EUR | 0.0% |
2020 Q4 | - EUR | 0.0% |
2020 FY | - EUR | 0.0% |
2020 Q2 | - EUR | 0.0% |
2019 Q4 | - EUR | 0.0% |
2019 Q2 | - EUR | 0.0% |
2019 FY | - EUR | 0.0% |
2018 Q2 | - EUR | 0.0% |
2018 FY | - EUR | 0.0% |
2018 Q4 | - EUR | 0.0% |
2017 Q2 | - EUR | 0.0% |
2017 FY | - EUR | 0.0% |
2017 Q4 | - EUR | 0.0% |
2016 Q4 | - EUR | 0.0% |
2016 FY | - EUR | 0.0% |
2016 Q2 | - EUR | 0.0% |
2015 Q4 | - EUR | 0.0% |
2015 FY | - EUR | 0.0% |
2015 Q2 | - EUR | 0.0% |
2014 Q4 | - EUR | 0.0% |
2014 FY | - EUR | 0.0% |
2014 Q2 | - EUR | 0.0% |
2013 Q4 | - EUR | 0.0% |
2013 Q3 | - EUR | 0.0% |
2013 Q2 | - EUR | 0.0% |
2013 FY | - EUR | -100.0% |
2013 Q1 | - EUR | 0.0% |
2012 Q2 | 1500.00 EUR | 0.0% |
2012 Q3 | 1500.00 EUR | 0.0% |
2012 Q4 | - EUR | -100.0% |
2012 FY | 6000.00 EUR | -71.43% |
2012 Q1 | 1500.00 EUR | 0.0% |
2011 Q3 | 5250.00 EUR | 0.0% |
2011 Q4 | 1500.00 EUR | -71.43% |
2011 Q2 | 5250.00 EUR | 0.0% |
2011 Q1 | 5250.00 EUR | 0.0% |
2011 FY | 21 Thousand EUR | 0.0% |
2010 Q4 | 5250.00 EUR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
ABIONYX Pharma SA | 4.64 Million EUR | 178.017% |
ABIVAX Société Anonyme | 4.62 Million EUR | 178.338% |
Adocia SA | 2.15 Million EUR | 268.372% |
Aelis Farma SA | 9.05 Million EUR | 139.982% |
Biophytis S.A. | - EUR | Infinity% |
Advicenne S.A. | 3.15 Million EUR | 214.884% |
genOway Société anonyme | 20.04 Million EUR | 118.058% |
IntegraGen SA | 12.53 Million EUR | 128.874% |
Medesis Pharma S.A. | 300.03 Thousand EUR | 1306.53% |
Neovacs S.A. | 533.41 Thousand EUR | 778.65% |
NFL Biosciences SA | - EUR | Infinity% |
Plant Advanced Technologies SA | 1.68 Million EUR | 315.282% |
Quantum Genomics Société Anonyme | 19.79 Thousand EUR | 18386.523% |
Sensorion SA | 4.74 Million EUR | 176.322% |
Theranexus Société Anonyme | 296.33 Thousand EUR | 1321.607% |
TME Pharma N.V. | 17 Thousand EUR | 21394.118% |
Valbiotis SA | 4.73 Million EUR | 176.484% |
TheraVet SA | 1.07 Million EUR | 435.79% |
Valerio Therapeutics Société anonyme | 1.8 Million EUR | 301.111% |
argenx SE | 1.13 Billion EUR | 100.319% |
BioSenic S.A. | 543 Thousand EUR | 766.667% |
Celyad Oncology SA | 102 Thousand EUR | 3649.02% |
DBV Technologies S.A. | - EUR | Infinity% |
Galapagos NV | 239.72 Million EUR | 101.51% |
Genfit S.A. | 28.56 Million EUR | 112.673% |
GeNeuro SA | - EUR | Infinity% |
Hyloris Pharmaceuticals SA | 2.08 Million EUR | 273.455% |
Innate Pharma S.A. | 51.9 Million EUR | 106.975% |
Inventiva S.A. | 17.47 Million EUR | 120.713% |
MaaT Pharma SA | 2.22 Million EUR | 262.478% |
MedinCell S.A. | 9.16 Million EUR | 139.52% |
Nanobiotix S.A. | 30.05 Million EUR | 112.043% |
Onward Medical N.V. | 532 Thousand EUR | 780.451% |
Oryzon Genomics S.A. | 14.19 Million EUR | 125.508% |
OSE Immunotherapeutics SA | 2.22 Million EUR | 262.551% |
Oxurion NV | 263 Thousand EUR | 1476.426% |
Pharming Group N.V. | 245.31 Million EUR | 101.476% |
Poxel S.A. | 1.98 Million EUR | 282.736% |
GenSight Biologics S.A. | 1.26 Million EUR | 385.714% |
Transgene SA | 1.18 Million EUR | 405.743% |
Financière de Tubize SA | - EUR | Infinity% |
UCB SA | 5.25 Billion EUR | 100.069% |
Valneva SE | 153.71 Million EUR | 102.355% |